T-20 launched in UK
Following approval in the EU on 28 May, T-20 (enfuvirtide, Fuzeon), was launched in the UK on 3 July 2003.
It is the first of a new class of entry inhibitors, and results from studies in treatment experienced patients have been closely reported previously in HTB.
EMEA European Public Assessment Reports
Roche press release
Enfuvirtide (T-20): predicting success and modelling survival benefits